Sponsors (9)
The bill clarifies and hardens the federal regulatory and enforcement posture toward mifepristone—providing clearer rules for providers and private remedies for harms—while reinstating a specific REMS and banning imports, which improves legal clarity but is likely to reduce access to medication abortion and increase legal and operational burdens for providers, carriers, and patients.
Hospitals, pharmacies, clinicians, and other providers get clearer, legally specified regulatory rules because the bill maintains/restores a specific REMS for mifepristone, reducing short-term regulatory uncertainty about dispensing and distribution.
Pregnant people seeking medication abortion will have mifepristone explicitly named in the law, clarifying that this medication is covered/regulated under the statute and reducing ambiguity about eligibility and access.
People harmed by illegally imported abortion medication gain private legal remedies—ability to recover compensatory and punitive damages and attorney fees—which increases avenues for compensation and creates a deterrent against unlawful importation.
People who rely on mailed or imported mifepristone—including those in states with restricted local access, uninsured people, or those without nearby providers—will lose an important avenue to obtain medication abortion, substantially reducing access to care for many.
Telehealth providers, pharmacies, and other remote dispensers face increased civil liability and legal exposure for out-of-state or cross-border shipments, likely raising compliance costs and causing some providers to stop shipping—further reducing access and raising prices.
The bill forces HHS to reinstate a specific past REMS within a tight timeframe, limiting the agency’s ability to update safety measures based on new evidence, potentially locking in outdated requirements and imposing administrative burdens on federal agencies.
Based on analysis of 5 sections of legislative text.
Introduced September 30, 2025 by Mary E. Miller · Last progress September 30, 2025
Requires the Department of Health and Human Services to restore the 2011 FDA Risk Evaluation and Mitigation Strategy (REMS) for the abortion drug mifepristone, forbids importing mifepristone into the United States (including by mail), and creates a federal private right of action allowing individuals who suffer physical or mental harm after using an unlawfully imported mifepristone product to sue telehealth providers, pharmacies, or other entities that knowingly imported or transported it. The bill defines “covered medication” as mifepristone and sets 90-day deadlines for reinstating the 2011 REMS and for the private-right-of-action provision to take effect.